Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 16.01 Million USD | 101.31% |
| 2021 | 7.95 Million USD | 2643.7% |
| 2020 | 289.86 Thousand USD | -33.34% |
| 2019 | 434.84 Thousand USD | 36.81% |
| 2018 | 317.85 Thousand USD | 496.92% |
| 2017 | 53.24 Thousand USD | 22.61% |
| 2016 | 43.42 Thousand USD | -8.55% |
| 2015 | 47.49 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 4 Million USD | 0.14% |
| 2023 Q2 | 3.19 Million USD | -20.2% |
| 2022 FY | 16.01 Million USD | 101.31% |
| 2022 Q2 | 3.99 Million USD | -0.22% |
| 2022 Q3 | 4.01 Million USD | 0.36% |
| 2022 Q1 | 4 Million USD | 0.06% |
| 2022 Q4 | 3.99 Million USD | -0.32% |
| 2021 Q1 | 86.49 Thousand USD | 11.3% |
| 2021 Q2 | 873.32 Thousand USD | 909.72% |
| 2021 Q3 | 2.99 Million USD | 242.45% |
| 2021 Q4 | 4 Million USD | 33.84% |
| 2021 FY | 7.95 Million USD | 2643.7% |
| 2020 Q3 | 71.54 Thousand USD | 13.97% |
| 2020 Q1 | 77.84 Thousand USD | -11.06% |
| 2020 FY | 289.86 Thousand USD | -33.34% |
| 2020 Q4 | 77.7 Thousand USD | 8.62% |
| 2020 Q2 | 62.77 Thousand USD | -19.37% |
| 2019 Q3 | 64.46 Thousand USD | -5.33% |
| 2019 Q1 | 214.76 Thousand USD | -6.48% |
| 2019 FY | 434.84 Thousand USD | 36.81% |
| 2019 Q4 | 87.52 Thousand USD | 35.79% |
| 2019 Q2 | 68.09 Thousand USD | -68.29% |
| 2018 Q4 | 229.63 Thousand USD | 150.93% |
| 2018 FY | 317.85 Thousand USD | 496.92% |
| 2018 Q3 | 91.51 Thousand USD | 43.72% |
| 2018 Q2 | 63.67 Thousand USD | -35.28% |
| 2018 Q1 | 98.38 Thousand USD | 53.08% |
| 2017 FY | 53.24 Thousand USD | 22.61% |
| 2017 Q1 | 22.44 Thousand USD | 202.75% |
| 2017 Q2 | 11.88 Thousand USD | -47.03% |
| 2017 Q3 | 11.5 Thousand USD | -3.21% |
| 2017 Q4 | 64.27 Thousand USD | 458.65% |
| 2016 FY | 43.42 Thousand USD | -8.55% |
| 2016 Q4 | 7413.00 USD | 20.99% |
| 2016 Q3 | 6127.00 USD | -64.22% |
| 2016 Q2 | 17.12 Thousand USD | 169.69% |
| 2016 Q1 | 6350.00 USD | -54.07% |
| 2015 Q4 | 13.82 Thousand USD | 491.61% |
| 2015 Q2 | 18.00 USD | -37.93% |
| 2015 Q1 | 29.00 USD | -99.94% |
| 2015 FY | 47.49 Thousand USD | 0.0% |
| 2015 Q3 | 2337.00 USD | 12883.33% |
| 2014 Q4 | 45.1 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1098.882% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -217.535% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 45.825% |
| Nascent Biotech, Inc. | 2.22 Million USD | -617.987% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2311.18% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 57.026% |
| Qrons Inc. | 643.67 Thousand USD | -2387.309% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4009.762% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 72.127% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3753.441% |
| Skye Bioscience, Inc. | 13.54 Million USD | -18.178% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 81.552% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -225.549% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6017.175% |
| SQZ Biotechnologies Company | 85.61 Million USD | 81.301% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -449.004% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -966.0% |
| Mesoblast Limited | 5.9 Million USD | -171.268% |
| Marizyme, Inc. | 19.23 Million USD | 16.786% |
| Genus plc | 147.7 Million USD | 89.16% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -82.365% |
| Pharming Group N.V. | 225.49 Million USD | 92.9% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -681.481% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1093.418% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -91.992% |
| ContraFect Corporation | 56.88 Million USD | 71.857% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -263.153% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -982.686% |
| IMV Inc. | 37.7 Million USD | 57.543% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -473.77% |
| MultiCell Technologies, Inc. | 567.42 USD | -2821484.893% |
| ONE Bio Corp. | 6.44 Million USD | -148.456% |
| Accustem Sciences Inc. | 3.74 Million USD | -327.348% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 81.372% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2909.658% |
| Q BioMed Inc. | 3.43 Million USD | -365.871% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 35.221% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -509.328% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1510.393% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 83.882% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -809.839% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -138.318% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -758.748% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 64140.948% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -772.447% |
| GB Sciences, Inc. | 1.42 Million USD | -1027.077% |
| Alpha Cognition Inc. | 9.7 Million USD | -64.959% |
| HST Global, Inc. | 140.9 Thousand USD | -11262.272% |
| CSL Limited | 3.44 Billion USD | 99.536% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1323.246% |
| Halberd Corporation | 74.84 Thousand USD | -21292.049% |
| Enzolytics Inc. | 2.17 Million USD | -634.581% |
| Agentix Corp. | 1.37 Million USD | -1067.134% |
| Resverlogix Corp. | 12.71 Million USD | -25.946% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -338.552% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.956% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1433.548% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -565.725% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -913.72% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -370.201% |
| AVAX Technologies, Inc. | 7.31 Million USD | -119.01% |
| Zenith Capital Corp. | 8.94 Million USD | -79.025% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.06% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -91801.94% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -552.064% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -9234.925% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -733.473% |
| Kadimastem Ltd | 2.41 Million USD | -564.294% |
| Helix BioMedix, Inc. | 1.97 Million USD | -711.864% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -47.329% |
| BioStem Technologies, Inc. | 22.97 Million USD | 30.314% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -8721.796% |
| LadRx Corporation | 3.81 Million USD | -320.019% |
| Cell Source, Inc. | 4.32 Million USD | -270.149% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1633.629% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1633.629% |
| NovAccess Global Inc. | 2.46 Million USD | -549.039% |
| Affymax, Inc. | 39.38 Million USD | 59.35% |
| Itoco Inc. | 919.14 Thousand USD | -1641.866% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -277.741% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1330.763% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2787.089% |
| CytoDyn Inc. | 18.05 Million USD | 11.34% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -63510.938% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -7174.801% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1027.647% |
| SYBLEU INC | 160.87 Thousand USD | -9851.911% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -781.466% |
| International Stem Cell Corporation | 5.27 Million USD | -203.742% |
| Bioxytran, Inc. | 3.82 Million USD | -319.1% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -30313.428% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -78601.455% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 55.853% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -889.508% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2075.792% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -414.633% |
| Neutra Corp. | 243.82 Thousand USD | -6466.39% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 8.288% |
| PureTech Health plc | 144.59 Million USD | 88.928% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 21.863% |
| IXICO plc | 4.7 Million USD | -240.137% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -81.997% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 86.403% |
| CSL Limited | 3.89 Billion USD | 99.589% |
| Cellectis S.A. | 97.32 Million USD | 83.549% |